Clinical Trials Logo

LGMD2I clinical trials

View clinical trials related to LGMD2I.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02841267 Completed - LGMD2I Clinical Trials

A Trial of PF-06252616 in Ambulatory Participants With LGMD2I

Start date: July 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The investigational product PF 06252616, a humanized anti myostatin monoclonal antibody that neutralizes myostatin (GDF8) is in development for the treatment of Limb Girdle Muscular Dystrophy 2I (LGMD2I) to preserve and/or improve muscle function. This study will provide the clinical assessment of the safety, tolerability, Pharmacokinetics and Pharmacodynamics of PF 06252616 following repeat IV doses in ambulatory adults with LGMD2I.